PHARMARON BEIJING CO., LTD. Pharmaron Beijing Co., Ltd. Stock Hong Kong S.E.
Equities
3759
CNE100003PG4
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.41 HKD | -0.42% |
|
-2.28% | -40.52% |
| Sales 2024 * | 12.65B 1.74B 13.62B | Sales 2025 * | 14.45B 1.99B 15.56B | Capitalization | 31.56B 4.35B 33.98B |
|---|---|---|---|---|---|
| Net income 2024 * | 1.71B 235M 1.84B | Net income 2025 * | 2.04B 281M 2.19B | EV / Sales 2024 * | 2.76 x |
| Net Debt 2024 * | 3.36B 463M 3.62B | Net Debt 2025 * | 3.14B 432M 3.38B | EV / Sales 2025 * | 2.4 x |
| P/E ratio 2024 * |
20.7
x | P/E ratio 2025 * |
17.4
x | Employees | - |
| Yield 2024 * |
1.09% | Yield 2025 * |
1.27% | Free-Float | 47.74% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | -0.42% | ||
| 1 week | -2.28% | ||
| Current month | -4.27% | ||
| 1 month | -14.14% | ||
| 3 months | -8.46% | ||
| 6 months | -37.35% | ||
| Current year | -40.52% |
1 week
9.21
9.96
1 month
9.0012.02
Current year
8.2516.10
1 year
8.2523.40
3 years
8.2594.22
5 years
8.2594.22
10 years
8.2594.22
| Managers | Title | Age | Since |
|---|---|---|---|
Xiao Qiang Lou
FOU | Founder | 55 | 04-06-30 |
Bei Zheng
FOU | Founder | 57 | 04-06-30 |
Bo Liang Lou
CEO | Chief Executive Officer | 60 | 04-06-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Kwan Hung Tsang
BRD | Director/Board Member | 60 | 19-08-14 |
Jia Qing Li
BRD | Director/Board Member | 51 | 16-10-26 |
Bo Liang Lou
CEO | Chief Executive Officer | 60 | 04-06-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.55% | 4 M€ | -27.92% | ||
| 0.57% | 1 M€ | -19.08% | - | |
| 0.26% | 2 M€ | -0.18% | - | |
| 0.09% | 2 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-11 | 9.41 | -0.42% | 2 252 500 |
| 24-06-07 | 9.45 | -2.17% | 2,473,100 |
| 24-06-06 | 9.66 | -0.31% | 2,938,900 |
| 24-06-05 | 9.69 | +0.62% | 2,504,907 |
| 24-06-04 | 9.63 | +4.11% | 4,598,400 |
Delayed Quote Hong Kong S.E., June 11, 2024 at 04:08 am EDT
More quotes
Pharmaron Beijing Co. is specialised in the research, development and manufacturing of small molecule drugs, cell therapies and gene therapies. Net sales break down by activity as follows:
- laboratory services (61.3%);
- development and production of chemical processes and formulations (23.5%);
- clinical research services (12.8%);
- other (2.4%);
Net sales are distributed geographically as follows: China (17.1%), Asia (2.6%), North America (64.2%), Europe (15.6%) and other (0.5%).
Calendar
2024-08-25
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
19.55
CNY
Average target price
24.15
CNY
Spread / Average Target
+23.52%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +50.41% | 56.95B | |
| +40.23% | 40.26B | |
| -7.51% | 39.32B | |
| -5.96% | 28.37B | |
| +12.26% | 26.45B | |
| -17.83% | 19.41B | |
| +30.79% | 12.54B | |
| +25.31% | 12.21B | |
| -1.19% | 12.15B |
- Stock Market
- Equities
- 300759 Stock
- 3759 Stock
